Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Mar 2023 According to an AriBio media release, David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from this trial at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD 2023).
04 May 2022 According to an AriBio media release, results from the study were reported at 14th Conference of Clinical Trials on Alzheimer's Disease (CTAD) in November 2021.
04 May 2022 According to an AriBio media release, David Greeley was the Primary Investigator of the study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com